Ixazomib Citrate is a prodrug of ixazomib, a protease inhibitor used as a second-line treatment of multiple myleoma. When in its biologically active form, ixazomib can inhibit angiogensis and induce apoptosis by activating apoptotic pathways and upregulating tumor-suppressor genes.